These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

946 related items for PubMed ID: 17982493

  • 1. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M, Mattsson J, Hassan Z, Karlsson N, LeBlanc K, Omazic B, Okas M, Sairafi D, Ringdén O.
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [Abstract] [Full Text] [Related]

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 3. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Jin JY, Lee JW, Kim CC.
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [Abstract] [Full Text] [Related]

  • 4. Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study.
    Hauzenberger D, Schaffer M, Ringdén O, Hassan Z, Omazic B, Mattsson J, Wikström AC, Remberger M.
    Tissue Antigens; 2008 Dec; 72(6):549-58. PubMed ID: 19000143
    [Abstract] [Full Text] [Related]

  • 5. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
    Teshima T, Matsuo K, Matsue K, Kawano F, Taniguchi S, Hara M, Hatanaka K, Tanimoto M, Harada M, Nakao S, Abe Y, Wake A, Eto T, Takemoto Y, Imamura M, Takahashi S, Ishida Y, Kanda Y, Kasai M, Takaue Y.
    Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
    [Abstract] [Full Text] [Related]

  • 6. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
    Carlens S, Ringdén O, Remberger M, Lönnqvist B, Hägglund H, Klaesson S, Mattsson J, Svahn BM, Winiarski J, Ljungman P, Aschan J.
    Bone Marrow Transplant; 1998 Oct; 22(8):755-61. PubMed ID: 9827972
    [Abstract] [Full Text] [Related]

  • 7. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.
    Remberger M, Naseh N, Aschan J, Barkholt L, LeBlanc K, Svennberg P, Ringdén O.
    Bone Marrow Transplant; 2003 Jul; 32(2):217-23. PubMed ID: 12838288
    [Abstract] [Full Text] [Related]

  • 8. Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors.
    Vigouroux S, Tabrizi R, Melot C, Coiffard J, Lafarge X, Marit G, Bouabdallah K, Pigneux A, Leguay T, Dilhuydy MS, Schmitt A, Boiron JM, Milpied N.
    Biol Blood Marrow Transplant; 2011 Jan; 17(1):93-100. PubMed ID: 20601038
    [Abstract] [Full Text] [Related]

  • 9. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kröger N, Zander AR.
    Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
    [Abstract] [Full Text] [Related]

  • 10. The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors.
    Remberger M, Mattsson J, Hentschke P, Aschan J, Barkholt L, Svennilson J, Ljungman P, Ringdén O.
    Bone Marrow Transplant; 2002 Dec; 30(11):761-8. PubMed ID: 12439699
    [Abstract] [Full Text] [Related]

  • 11. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation.
    Remberger M, Svahn BM, Mattsson J, Ringdén O.
    Transplantation; 2004 Jul 15; 78(1):122-7. PubMed ID: 15257050
    [Abstract] [Full Text] [Related]

  • 12. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
    Dhédin N, Chamakhi I, Perreault C, Roy DC, Sauvageau G, Ducruet T, Busque L, Fish D, Bélanger R, Roy J.
    Exp Hematol; 2006 Jan 15; 34(1):107-14. PubMed ID: 16413397
    [Abstract] [Full Text] [Related]

  • 13. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
    Satwani P, Baldinger L, Freedman J, Jacobson JS, Guerra J, van de Ven C, Morris E, Garvin J, George D, Bradley MB, Bhatia M, Tallamy B, Schwartz J, Jin Z, Cairo MS.
    Biol Blood Marrow Transplant; 2009 Dec 15; 15(12):1587-95. PubMed ID: 19896083
    [Abstract] [Full Text] [Related]

  • 14. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children.
    Kondo M, Kojima S, Horibe K, Kato K, Matsuyama T.
    Bone Marrow Transplant; 2001 Apr 15; 27(7):727-30. PubMed ID: 11360113
    [Abstract] [Full Text] [Related]

  • 15. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.
    Banna GL, Aversa S, Sileni VC, Favaretto A, Ghiotto C, Monfardini S.
    Crit Rev Oncol Hematol; 2004 Sep 15; 51(3):171-89. PubMed ID: 15331077
    [Abstract] [Full Text] [Related]

  • 16. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P, Piñana JL, Valcárcel D, Querol L, Martino R, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.
    Biol Blood Marrow Transplant; 2009 Nov 15; 15(11):1439-46. PubMed ID: 19822304
    [Abstract] [Full Text] [Related]

  • 17. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR.
    Biol Blood Marrow Transplant; 2001 Nov 15; 7(11):620-30. PubMed ID: 11760150
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation.
    Seidel MG, Fritsch G, Matthes-Martin S, Lawitschka A, Lion T, Pötschger U, Rosenmayr A, Fischer G, Gadner H, Peters C.
    Haematologica; 2005 Oct 15; 90(10):1405-14. PubMed ID: 16219578
    [Abstract] [Full Text] [Related]

  • 19. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation.
    Remberger M, Svahn BM, Hentschke P, Löfgren C, Ringdén O.
    Bone Marrow Transplant; 1999 Oct 15; 24(8):823-30. PubMed ID: 10516691
    [Abstract] [Full Text] [Related]

  • 20. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.
    Willems E, Baron F, Seidel L, Frère P, Fillet G, Beguin Y.
    Bone Marrow Transplant; 2010 Apr 15; 45(4):689-93. PubMed ID: 19718063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.